Abstract. Steroid receptors and enzymes that control steroid synthesis and metabolism work together to control vital hormonal functions. Crystallographic data on steroids having high affinity for estrogen, progestin, and corticoid receptors suggest that receptor binding is primarily the result of a high level of complementarity between the receptor and the steroidal A-ring. The crystal structures of two steroid dehydrogenase enzymes reveal the location of the active site, the position of the conserved catalytic triad (Tyr-Lys-Ser), a possible mechanism of keto-hydroxyl interconversion and the basis for selectivity, A complex between carbenoxolone and one of the enzymes reveals how the active ingredient in licorice inhibits this enzyme as well as human 1 Ip-hydroxysteroid dehydrogenase (1 Ip-HSD). The complex reveals that the inhibitor fills the substrate binding pocket, displaces the cofactor and accepts a hydrogen bond from a tyrosine residue, one of less than 20 strictly conserved residues in the family of enzymes, explaining how ingestion of licorice can produce hypertension.
Introductioa
Steroid hormones play a vital role in a wide variety of essential physiological processes including cell growth, sexual development, maintenance of salt balance and sugar metabolism. They have also been implicated in responses to stress and sexual imprinting of the fetal brain. Abnormalities in steroid hormone synthesis, metabolism and receptor interaction contribute to a variety of diseases. Synthetic steroids are used extensively in fertility control, as anti-inflammatory agents and immunosuppressants. Antihormones that interfere with the synthesis, metabolism and receptor binding of steroids are useful in some forms of chemotherapy. A careful examination of the molecular structures and three-dimensional shapes of the hormones, antihormones, chemicals and drugs that compete for a common binding site on a specific receptor, binding protein or metabolizing enzyme can provide information on structural features that influence hormonal response.
Crystallographic data on over lo00 steroids ( 1,2) provide information concerning preferred conformations, relative stabilities and substituent influence on the interactive potential of steroid hormones and analogs. Systematic conformational analysis of subsets of these data having common structural features suggests that steroids crystallize in global minimum energy conformations or local minimum energy conformations that axe less than two kcal mol-l above the global minimum (3-5). If the receptorbound steroid is also in its minimum energy conformation, then it should be possible to compare the crystallographically observed structures of a series of steroids that compete for a specific binding site and determine the structural features that are essential for binding, the relative location of functional groups that interact with the receptor, how tight a fit exists between the steroid and the receptor, and to what extent the binding site of the receptor protein is flexible. This paper describes a proposed empirical model for steroid receptor binding based on structure-activity comparisons and a description of efforts to model the steroid binding pocket in a family of hydroxysteroid dehydrogenase enzymes.
Steroid Structu re. ReceD tor Binding and Hormone Action Examination of the structures of compounds having high affinity for estrogen, progestin, and corticoid receptors led to the suggestion that steroid-receptor binding is primarily the result of interactions between the receptor and the steroidal A ring (5) (6) (7) (8) . An illustration of the proposed fit between the phenolic A ring present in almost all compounds exhibiting estrogenic activity and a binding site on the receptor is illustrated in Figure 1 , Activity of estrogens, progestins, and corticoids might be controlled by the D ring.
Possible mechanisms include ( 1) inducing or stabilizing an essential conformational state in the receptor (allostery), (2) influencing the aggregation state of the receptor, or (3) participating in a direct interaction with DNA or chromatin (9) . Antagonists that compete for these receptor sites appear to have the A-ring composition and conformation necessary for receptor binding but lack the D-ring conformational features and functional groups that induce or stabilize subsequent receptor functions (10) . Antagonists also include compounds with A-ring conformations appropriate for binding but have other structural features that interfere with subsequent receptor functions essential to activitv. In contrast. androgen recevtor binding data ( I 1) and molecdar modeling studies suggest that for androgens a D-ring bindindA-ring icting mod4 is more appropriate.
3eroid Protein Interactions and Binding Information concerning the molecular details of steroid-protein interactions can be obtained from X-ray analysis of crystalline Eomplexes of proteins with appropriate steroid agonists and antagonists, and from X-ray studies of model complexes of steroids with amino acids. The structure of uteroglobin. a progesterone-binding protein (12) provides a useful model for other steroid binding proteins, although no steroid war. present in its presumed binding pocket. Quantities of pure stable, intact steroid receptor proteins, sufficient to allow single crystal x-ray analysis are not yet available; however, the crystal structures of complexes between the DNA-binding domain of the giucocorticoid receptor and specific recognition elements from DNA have been reported (13) . Crystal structures of three enzymes that have steroids as their primary substrate have been reported. The steroid-binding site has been tentatively identified in one of these by imaging a bound inhibitor (14) and inferred in the others on biochemical grounds (l5,lfij. The rest of the paper will be concerned with the mechanism of action of these enzymes.
Licorice. Ulcers. Hieh Blood Pressure and Short r h ain Dehvdroeenase Enzvmes Studies of three-dimensional structures of a family of dehydrogenase enzymes that influence mammalian reproduction. hypertension, neoplasia and digestion can reveal the mechanisms by which these enzymes control circulating levels of steroids and other hormones and permit the design of ligands that will have selectivity of action. One member of the family controls cortisoVcortisone balance and influences hypertension (17) . another controls estradiollestrone balance and influences growth of certain tumors (18) and a third controls prostaglandin metabolism and is implicated in development of ulcers (19) . Although these enzymes have different substrate specificities they can be inhibited by common agents. Of particular interest is the inhibition of several members of the family by an active ingredient in licorice, glycyrrhizic acid and its metabolite carbenoxolone (20) . Licorice has a therapeutic effect on digestion reputedly viu inhibition of prostaglandin dehydrogenase but excess consumption of licorice is dangerous for people taking medication for hypertension. We have determined the crystal structures of various forms of two members of the short-chain dehydro enase family, human estrogenic 17P-hydroxysteroid dehydrogenase (I7PHSD) (2 I) and bacterial 3a,20~-hydroxysteroid dehydrogenase (3a,20P-HSD) (22.23). The threedimensional smctures reveal the position of the conserved catalytic mad (Tyr-Lys-Serj in the active site, a possible mechanism of kern-hydroxyl interconversion. the mechanism of inhibition bv carbenoxolone, and the basis for 17P-HSD selectivity.
X y l ( e r 0 id D e h v d r o e w Bacterial 3a.20B-hrdroxssteroid dehydrogenase rcvcrsiblv oxidizes the 3a and 200 hvdroxvl QIOUDS of androstanes and pregnanes. It was the first short-chain dehydrogenase to be &die; 6y k-ray crystallography. The asymmetric unit of the crystal contains four monomers, each with 253 amino acid residues, 38 water molecules, and 176 cofactor atoms belonging to four NAD molecules -one for each subunit. The three-dimensional structure of the monomer of 3a.20P-HSD and the observed location of the cofactor is illustrated in Figure 2 and the organization of the tetramer illustrated in Figure 3 . The catalytic site contains residues Tyr152 and Lys156. These two amino acids are strictly conserved in the short-chain dehydrogenase superfamily (24) . Modeling studies with a cortisone molecule in the catalytic site (Figure 4) suggest that the Tyr152, and Lys156 side chains promote electrophilic attack on the ((30-0) carbonyl oxygen atom, thus enabling the carbon atom to accept a hydride from the reduced cofactor. The Ser139, conserved in steroid dehydrogenases could be involved in subshate binding or in some unknown function.
Qrbenouolone Comolex of 3a. This structure presents the frst direct evidence of binding of a substrate-like moiety in the catalytic site of a member of this family of enzymes. The structure of the complex of 3a,20&HSD with the active ingredient in licorice, reveals that the steroid molecule binds in the region prmiously identified as the catalytic site, thereby preventing substrate binding. Carbenoxolone also competes effectively with the binding of the essential cofactor nicotinamide adenine dmucleotide. The binding interactions include the formation of a specific hydrogen bond with the invariant Tyr152. Together with the site-directed mutagenesis study that showed tyrosine to be essential for catalytic activity (25) (26) (27) . this result suggests that Tyr152 could interact with steroidal substrates in a similar fashion. Analogous binding of carbenoxolone to human renal 1 IP-HSD is reported to be a contributing factor in licorice-induced hypertension. Detailed information on the sh'ucture of holo. apo, and inhibited forms of the shon-chain dehydrogenase family of enzymes will be critical to determining their mechanisms of action and the design of selective and specific inhibitors. Such inhibitors could have direct therapeutic applications as drugs with reduced side effects for the treatment of certain hormone related diseases.
Dehydr--ogeni c I7D-hydroxysteroid dehydrogenase (type I 17p-HSD) catalyzes the last stcp in the biosynthesis of 17p-estradioi from the less potent 6strogen,-esuone; it is an attractive target for the design of inhibitors of estrogen production and tumor growth. This human enzyme shares less than 15% sequence identity with a bacterial 3a,20P-HSD. The amino acid sequence of 17P-HSD also differs from that of bacterial 3m20P-HSD by insertions of 11 and 14 residues and the addition of 52 more residues at the C terminus. The 2.20A resolution structure of type I I7P-HSD, the first mammalian steroidogenic enzyme studied by X-ray crystallographic techniques, reveals a fold characteristic of the short-chain dehydrogenases. The active site contains a Tyr-X-X-X-Lys sequence (where X is any amino acid) and a serine residue, features that are conserved in short-chain steroid dehydrogenases. The structure also contains thrm a-helices and a helix-turn-helix motif, not observed in short-chain dehydrogenase structures reported previously.
Our results demonstrate that despite only about 15% s uence identity and the presence of two major insertions and additional residues at the C terminus, I g -H S D has the same overall fold as bacterial 3a,20P-HSD and mammalian DHPR. The additional residues in 17P-HSD form two helix-turn-helix motifs, and these constitute a 'substrate-recognition domain' bordering the active site at the end of the steroid-binding cavity opposite the cofactor-binding site and the catalytic residues. The apparent amphiphilic nature of the additional helices and thei :opological location are consistent with the obselved association of the enzyme with microsomal membranes. Modeling 17pestradiol at the active site suggests that the 3-hydroxyl end of the subsnate. which is at the end of the molecule opposite to where the oxidoreductive reactions occur, fits into a cavity in this domain and forms a specific hydrogen bond with a histidine side chain (Figure 7) . Comparable substrate-recognition features are not present in the active site of the bacterial enzyme, allowing it to process a greater range of substrates. The proposed transition state of the enzyme is consistent with the relative locations of the recognition histidine (a histidine side chain that makes a specific hydrogen bond with the non-reactive 3-hydroxyl end of the substrate) and the catalytic Tyr-Ser-Lys triad in the active site (Figure 8 
